TRANSCEND FL (NCT04245839) is an open-label, global, multicenter, Phase 2, single-arm study to determine the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non ...

Despite the extensive adverse effects, the commission claims that the CS for Interior Kithure Kindiki, Lands CS and Water CS ...

This is the second accelerated approval the FDA has granted to Bristol Myers Squibb’s chimeric antigen receptor T-cell ...

Hepatocellular carcinoma screening was associated with earlier detection and improved survival, even after accounting for ...

A strange thing happened a few years ago when Christine Longnecker, who teaches horseback riding in and around Erie County, ...

PRESS RELEASEAB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR MASITINIB IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory ...

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...

Rothkopf, memorable as the painfully shy Laura Wingfield in Bridge Street’s October production of “The Glass Menagerie,” ...

Stephens started coverage of Blueprint Medicines (BPMC) with a buy rating and a place on its best idea list, citing the company's Ayvakit franchise. Read more here.

First data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...